Research programme: antibody drug conjugates - Glythera

Drug Profile

Research programme: antibody drug conjugates - Glythera

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glythera
  • Class Antibodies; Antineoplastics; Biological toxins; Immunoconjugates
  • Mechanism of Action Cell death stimulants; Cyclin dependent kinase 19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 26 Sep 2017 Glythera secures worldwide development and commercialisation license for CDK11 inhibitor payload series from Cancer Research UK for development of antibody-drug conjugates in the treatment of Cancer
  • 07 Jun 2017 Early research in Cancer in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top